用双位点单抗免疫酶法测定CK—MB质量

应用免疫单抗ＥＬＩＳＡ法测定ＣＫ－ＭＢ的质量，与免疫抑制法及电泳法进行了比较，其准确性和精密性均符合临床要求。急性心肌梗塞（ＡＭＩ）２５份血标本测定结果与免疫抑制法相关方程为Ｙ＝１．０７７Ｘ－４．３，ｒ＝０．９９６，免疫酶法比免疫抑制法更具有特异性。     

冠心病患者实施同型半胱氨酸检测的临床意义

目的：探讨同型半胱氨酸浓度水平的检测对于早期诊断急性心肌梗死的应用价值。方法选择2013年1月～2013年12月确诊为冠心病的患者53例为试验组,选择同期进行体检且结果显示为健康的50例为对照组,试验组和对照组均进行同型半胱氨酸、肌酸激酶、肌酸激酶同工酶的测定,对结果进行综合分析。结果试验组的患者血清同型半胱氨酸、肌酸激酶、肌酸激酶同工酶的浓度水平较对照组均有明显上升趋势,差异有统计学意义（P＜0.05）;阳性检出率分析,试验组患者的的同型半胱氨酸、肌酸激酶和肌酸激酶同工酶的检测结果阳性率分别为84.91%（45/53）、81.13%（43/53）、83.02%（44/53）,同型半胱氨酸检测结果阳性率分别与肌酸激酶、肌酸激酶同工酶两两比较,差异无统计学意义（P＞0.05）;临床标本相关性分析,同型半胱氨酸检测结果和临床诊断结果的相关性好,Kappa值等于0.81。结论同型半胱氨酸是一种辅助诊断冠心病的有效指标,具有较好的灵敏度和临床符合性。     

Urine screening for patients with developmental disabilities detected a patient with creatine transporter deficiency due to a novel missense mutation in SLC6A8

Creatine transporter deficiency (CTD) is an example of X-linked intellectual disability syndromes, caused by mutations in SLC6A8 on Xq28. Although this is the second most frequent genetic cause of intellectual disabilities in Europe or America after Fragile X syndrome, information on the morbidity of this disease is limited in Japan. Using the HPLC screening method we have established recently, we examined samples of urine of 105 patients (73 males and 32 females) with developmental disabilities at our medical center. And we have found a family with three ID boys with a novel missense mutation in SLC6A8. This is the second report of a Japanese family case of CTD. A systematic diagnostic system of this syndrome should be established in Japan to enable us to estimate its frequency and treatment.     

Detection of acute myocardial infarction by a new, sensitive and rabid method for determination of creatine kinase B-subunit activity

An immunoinhibition method for the assay of creatine kinase(CK) isoenzymes by continuous monitoring of the ATP formationin the CK reaction by a purified firefly luciferase reagenthas been developed. The sensitivity of the firefly assay ofATP makes it possible to assay CK-B subunit activity (CK-B)in serum down to 1 U/l. In healthy individuals CK-B varied between 2 and 12, mean 3U/l. A wide range of CK-B activity was observed after acutemyocardial infarction (AMI), intramuscular injection and surgerywith overlapping between these different categories. Thereforethe maximal change in CK-B activity (CK-B) was studied in 98patients admitted to a coronary care unit. In all 57 patientswithout a subsequent diagnosis of AMI according to conventionalcriteria CK-B was < 5 U/l. In all 41 patients with AMI CK-Bwas 5 U/l. In all healthy individuals CK-B was < 2 U/l.CK-B 5 U/l was found after i.m. injection and different kindsof surgery in three out of 60 patients. Thus, the present method for determination of CK activity hasbeen shown to possess high precision in low activities, to beas rapid as conventional methods and to be simple enough tobe used in a routine laboratory. With these properties the methodshould be suited for early diagnosis and early exclusion ofeven very small AMIs.     

磷酸肌酸钠和1,6-二磷酸果糖治疗小儿心肌损害效果观察

目的观察磷酸肌酸钠和1,6-二磷酸果糖治疗小儿心肌损害的疗效。方法选择2010年10月—2013年10月因心肌损害进行药物治疗的120例患儿,随机分为对照组、磷酸肌酸钠组和二磷酸果糖组各40例。患儿入院后立即进行常规治疗,服用大量的维生素C、葡萄糖、辅酶Q10和ATP,病毒感染者进行抗病毒治疗,如患儿出现心律失常、心力衰竭应该进行及时治疗。对照组进行常规治疗,磷酸肌酸钠组加用磷酸肌酸钠,50 mg/kg溶于25 ml生理盐水中,静脉滴注,1次/d;二磷酸果糖组加用1,6-二磷酸果糖200 mg/kg溶于100 ml生理盐水中,静脉滴注,1次/d。三组均连续治疗2周。观察三组患儿治疗前后的CK、CK-MB、LDH、CTnI的变化及心电图的恢复情况。计量资料采用t检验,计数资料采用χ2检验,P0.05为差异有统计学意义。结果治疗后CK、CK-MB、LDH、CTnI均较治疗前明显下降,与对照组比较,磷酸肌酸钠组[(339.86±52.90)、(0.85±0.09)、(183.22±43.32)、(13.32±6.08)U/L]和二磷酸果糖组[(350.61±48.80)、(1.12±0.05)、(192.71±39.67)、(15.41±5.13)U/L)]下降更明显,差异均有统计学意义(均P0.05)。磷酸肌酸钠组和二磷酸果糖组总有效率(95.0%、92.5%)明显高于对照组,差异均有统计学意义(均P0.05)。结论磷酸肌酸钠和1,6-二磷酸果糖对小儿心肌损害具有较好疗效,可为临床用药提供参考。     

慢性肾功能衰竭合并急性左心衰竭患者心肌酶和肌钙蛋白的意义分析

目的 探讨慢性肾功能衰竭合并急性左心衰竭患者心肌酶和肌钙蛋白升高的临床意义.方法 选择慢性肾功能衰竭合并急性左心衰竭患者38例（试验组）,另选取同期未发生急性左心衰竭的慢性肾功能衰竭患者42例作为对照组,检测两组肌酸激酶同工酶（CK-MB）、天冬氨酸氨基转移酶（AST）、心肌肌钙蛋白Ⅰ（cTnI）、肌酐的变化,并记录患者院内预后.结果 试验组CK-MB、cTnI均较对照组明显升高[（36.23±14.27） U/L比（14.71士8.27）U/L、（11.26±5.04）μg/L比（5.24±2.31）μg/L],差异有统计学意义（P＜0.05）;两组AST、肌酐水平均较正常值明显升高,但两组间比较差异无统计学意义（P＞0.05）;试验组院内病死率明显高于对照组[47.37％（18/38）比16.67％（7/42）],差异有统计学意义（P＜0.01）;多因素分析结果显示,CK-MB、cTnI均是影响慢性肾功能衰竭合并急性左心衰竭患者预后的独立危险因素（r=5.03,3.27,P＜0.05）.结论 慢性肾功能衰竭合并急性左心衰竭患者心肌酶和肌钙蛋白的升高对预后有评估作用.     

Weak diagnostic performance of troponin,creatine kinase and creatine kinase-MB to diagnose or exclude myocardial infarction after successful resuscitation

Background

The aim of this study is to evaluate the diagnostic accuracy of the cardiac injury markers troponin (TNT), creatine kinase (CK) and creatine kinase-MB (CK-MB) to diagnose or exclude acute myocardial infarction after cardiac arrest.

Methods

226 patients who underwent diagnostic coronary angiography after sudden cardiac arrest were analyzed retrospectively. Levels of TNT, CK and CK-MB on admission and 6 h, 24 h and 36 h later were retrieved from the files and compared with the results of coronary angiography.

Results

Acute myocardial infarction (AMI) as well as non-AMI patients showed increasing levels of TNT and CK after resuscitation, although the AMI group showed significantly higher TNT and CK levels. Receiver operator curves were calculated to determine the diagnostic precision of TNT, CK and CK-MB to differentiate AMI and non-AMI patients. All analyzed markers yielded mediocre diagnostic precision with an area under the ROC curve of 0.7020, 0.6802 and 0.6508 for 6 h TNT, CK and CK-MB, respectively. Applying a modified cut-off of 1 μg/l the 6 h TNT measurement had a sensitivity of 70.9% and specificity of 61.2% to diagnose AMI after cardiac arrest. Using CK 800 U/l as cut-off level resulted in a sensitivity of 62.5% and specificity of 73.7%, CK-MB levels higher than 100 U/l yielded a sensitivity of 58.8% and specificity of 72.7%.

Conclusion

Cardiac injury markers cannot be used to reliably diagnose or rule out AMI after resuscitation. Consequently we propose that indication for coronary angiography should be extended to all patients without a certain alternative diagnosis explaining the occurrence of cardiac arrest.     

COVID-19患者实验室指标变化的观察研究

目的总结新型冠状病毒肺炎(corona virus disease 2019,COVID-19)患者治疗前后实验室指标变化趋势。方法选择2020年1-2月宝鸡市中心医院感染科确诊的13例COVID-19患者为研究对象,回顾分析实验室指标在治疗前后的变化情况。结果治疗前后白细胞总数(WBC)、血小板(PLT)、C反应蛋白(CRP)、红细胞沉降率(ESR)、肌酸激酶(CK)、α羟丁酸脱氢酶(α-HBDH)、白细胞介素6(IL-6)、淀粉样蛋白A(SAA)、肌红蛋白(Mb)水平存在明显差异(P<0.05或P<0.01)。WBC、淋巴细胞计数(LYMP)、PLT、CRP、ESR、CK、α-HBDH、直接胆红素(DBIL)、IL-6、SAA、便潜血试验异常率在治疗前后存在显著差异(P<0.05或P<0.01)。结论WBC、PLT、CRP、ESR、CK、α-HBDH、IL-6、SAA、Mb指标变化可用来评估COVID-19患者治疗的有效性,可作为疾病预后的评估指标;而WBC、LYMP、PLT、CRP、ESR、CK、α-HBDH、DBIL、IL-6、SAA、便潜血试验可作为其早期诊断及辅助诊断指标。